Information Provided By:
Fly News Breaks for September 13, 2019
LPTX
Sep 13, 2019 | 08:40 EDT
Raymond James analyst David Novak resumed coverage on Leap Therapeutics with an Outperform and $5 price target. Novak believes Leap is in the early stages of identifying specific patient subpopulations most likely to benefit from treatment with its two novel immuno-oncology assets, TRX518 and DKN-01, both of which have generated compelling anti-tumor activity as monotherapies and in combination with chemotherapeutics and other immunotherapies.
News For LPTX From the Last 2 Days
There are no results for your query LPTX